Provided by Tiger Trade Technology Pte. Ltd.

Prime Medicine, Inc.

3.71
+0.460014.15%
Post-market: 3.69-0.0200-0.54%18:17 EDT
Volume:3.32M
Turnover:11.91M
Market Cap:669.69M
PE:-3.42
High:3.71
Open:3.30
Low:3.29
Close:3.25
52wk High:6.94
52wk Low:2.67
Shares:180.51M
Float Shares:116.00M
Volume Ratio:0.93
T/O Rate:2.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0853
EPS(LYR):-1.3521
ROE:-373.29%
ROA:-46.52%
PB:16.82
PE(LYR):-2.74

Loading ...

TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647

TIPRANKS
·
Jul 09

Resolution in favor of Prime has limited impact to Beam, says BofA

TIPRANKS
·
Jul 08

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME)

TIPRANKS
·
Jul 08

Prime Medicine Posts Corporate Deck Highlighting Prime-editing Platform, Lead Programs in Wilson Disease and AATD

Reuters
·
Jul 08

Prime Medicine Wins Arbitration with Beam over AATD Therapy PM647

Reuters
·
Jul 08

Prime Medicine, - Initial Clinical Data for Pm647 Expected in 2027

THOMSON REUTERS
·
Jul 08

Prime Medicine, - Arbitration Tribunal Confirms Prime Medicine's Right to Develop and Commercialize Pm647 in Aatd

THOMSON REUTERS
·
Jul 08

Prime Medicine, - Owes no Monetary Damages to Beam Therapeutics

THOMSON REUTERS
·
Jul 08

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

THOMSON REUTERS
·
Jul 08

Prime Medicine, - to Submit Ind And/or Cta for Pm647 in Q3 2026

THOMSON REUTERS
·
Jul 08

Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine today

TIPRANKS
·
Jul 08

CYTK, PRME, DOCS, WBD, LQDA Trending With Analysts

TIPRANKS
·
Jul 04

HC Wainwright Upgrades Prime Medicine to Buy From Neutral, $8 Price Target

MT Newswires Live
·
Jun 29

Prime Medicine Raised to Buy from Neutral by HC Wainwright & Co.

Dow Jones
·
Jun 29

Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)

TIPRANKS
·
Jun 24

Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Prime Medicine, Inc. (PRME)

TIPRANKS
·
Jun 23

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Pm359 for the Treatment of Chronic Granulomatous Disease (Cgd)

THOMSON REUTERS
·
Jun 22

Prime Medicine, Inc. (PRME) Receives a Hold from Morgan Stanley

TIPRANKS
·
Jun 22

Prime Medicine says New Zealand clears clinical trial application for Wilson disease therapy PM577a

Reuters
·
Jun 18

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for Pm577a in H1069q-Mutated Wilson Disease

THOMSON REUTERS
·
Jun 18